Cagliari
Cagliari
Cagliari, Italy107 results · Page 1 of 5
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care | Craniocerebral Trauma, Injuries, Acute Brain, brain disorder, brain injury, central nervous system disorder, injury, nervous system disorder, nervous system injury | Recruiting | Not stated | 2026-10-09 | NCT04905264 | |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 3 | 2026-10-08 | NCT07222137 | |
| Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease | Steno-occlusive Disease | Recruiting | Phase 3 | 2026-10-07 | NCT07348640 | |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-10-07 | NCT05243797 | |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Bone Diseases, Developmental, Camurati-Engelmann disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, bone disorder, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, hereditary disease, laryngeal disorder, musculoskeletal system disorder, neoplasm, osteochondrodysplasia, otorhinolaryngologic disease, respiratory system disorder, squamous cell carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-10-02 | NCT06788990 | |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, proteinuria, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06291376 | |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06531824 | |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT06943872 | |
| Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04793958 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04770779 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04770753 | |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT03466411 | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Active, not recruiting | Phase 3 | 2026-09-28 | NCT03451851 | |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | NCT07227454 | |
| A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT07196722 | |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, squamous cell carcinoma | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06525220 | |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 4 | 2026-09-24 | NCT06651970 | |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infarction, Male Urogenital Diseases, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, ischemic disease, kidney disorder, kidney failure, metabolic disease, myocardial infarction, myocardial ischemia, peripheral arterial disease, peripheral vascular disease, urinary system disorder, vascular disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT05485961 | |
| A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-21 | NCT04096066 | |
| Emotional Allodynia Questionnaire (AEQ) in Fibromyalgia (PEARL) | Chronic Pain, Neurologic Manifestations, Nociplastic Pain, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, fibromyalgia, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, rheumatic disorder | Recruiting | Not stated | 2026-09-11 | NCT07677631 | |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | gastroesophageal junction adenocarcinoma | Recruiting | Phase 3 | 2026-09-11 | NCT06764875 | |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-08 | NCT05929222 | |
| A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, interstitial lung disease, lung disorder, respiratory system disorder, skin disorder, systemic sclerosis | Recruiting | Phase 2 / Phase 3 | 2026-09-08 | NCT05878717 | |
| Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance | diffuse large B-cell lymphoma | Active, not recruiting | Phase 2 | 2026-09-08 | NCT03731234 | |
| Italian Network MDS Registry | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic/myeloproliferative disease | Recruiting | Not stated | 2026-09-04 | NCT02808858 |